Jan-Philipp Cieslik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan-Philipp Cieslik has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Hans Neubauer
Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
4 shared publications - Tanja Fehm
Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
4 shared publications - Hannah Asperger
Department of Vascular Neurology, University Hospital Bonn , Bonn
3 shared publications André Franken
2 shared publications- Dieter Niederacher
Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany
2 shared publications Maggie Banys-Paluchowski
2 shared publications
Latest Publications
- 18 September 2026
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 23 (03) , 220-222
Internationale Bedarfsanalyse zur Versorgung der idiopathischen granulomatösen Mastitis – Ausgangspunkt für ein internationales Register
- 18 September 2026
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 23 (03) , 220-222
Internationale Bedarfsanalyse zur Versorgung der idiopathischen granulomatösen Mastitis – Ausgangspunkt für ein internationales Register
- Open Access
- 19 March 2026
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 86 (04) , 395-402
Cervical Dysplasia Diagnosed in Pregnancy – A Pre- and Postpartum Analysis
Cervical lesion regression and persistence rates are notably high. This study aims to analyse postpartum changes in cervical dysplasia diagnosed during pregnancy. Furthermore, the impact of age, tobacco use, and mode of delivery on cervical findings was assessed as the existing data is inconclusive. This retrospective analysis included pregnant women diagnosed with cervical dysplasia, with complete pre- and postpartum colposcopy, cytology, and histological findings, along with HPV status. Postpartum rates of regression, persistence, and progression were determined and the influence of age, tobacco use, and mode of delivery on cervical preneoplastic lesions was analysed using ordered logistic regression. The study included 102 patients treated between 2010 and 2015 with complete pre- and postpartum cytology and/or biopsy data. Postpartum evaluation showed a regression rate of 45.1%, persistence in 52%, and progression in 2.9%. No significant influence on these rates was observed for age (p = 0.255), tobacco use (p = 0.310), or mode of delivery (p = 0.217). Our findings support the recommended conservative approach of managing cervical lesions during pregnancy which advocates for continuation of the pregnancy with regular monitoring and postpartum surgery if necessary. If invasive cancer can be excluded, the mode of delivery should be based on obstetric criteria, irrespective of cervical findings.
- 19 March 2026
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 86 (04) , 395-402
Open AccessCervical Dysplasia Diagnosed in Pregnancy – A Pre- and Postpartum Analysis
Cervical lesion regression and persistence rates are notably high. This study aims to analyse postpartum changes in cervical dysplasia diagnosed during pregnancy. Furthermore, the impact of age, tobacco use, and mode of delivery on cervical findings was assessed as the existing data is inconclusive. This retrospective analysis included pregnant women diagnosed with cervical dysplasia, with complete pre- and postpartum colposcopy, cytology, and histological findings, along with HPV status. Postpartum rates of regression, persistence, and progression were determined and the influence of age, tobacco use, and mode of delivery on cervical preneoplastic lesions was analysed using ordered logistic regression. The study included 102 patients treated between 2010 and 2015 with complete pre- and postpartum cytology and/or biopsy data. Postpartum evaluation showed a regression rate of 45.1%, persistence in 52%, and progression in 2.9%. No significant influence on these rates was observed for age (p = 0.255), tobacco use (p = 0.310), or mode of delivery (p = 0.217). Our findings support the recommended conservative approach of managing cervical lesions during pregnancy which advocates for continuation of the pregnancy with regular monitoring and postpartum surgery if necessary. If invasive cancer can be excluded, the mode of delivery should be based on obstetric criteria, irrespective of cervical findings.
- Open Access
- 12 February 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (8) , 2451-2462
MaGIC-OT: an AI-guided optical tweezers platform for autonomous single-cell isolation in microfluidic devices
Automating the isolation of rare cells such as circulating tumour cells (CTCs) within crowded microfluidic environments remains a bottleneck in liquid biopsy workflows. Optical tweezers offer contact-free, selective manipulation but traditionally rely on expert operators. We present MaGIC-OT (machine-guided isolation of cells using optical tweezers), a platform that integrates classical path planning and deep reinforcement learning (DRL) to automate single-cell manipulation inside a microfluidic chip. We built a high-fidelity simulation to train and benchmark control policies and show that cooperative, human-in-the-loop training improves DRL performance. Trained agents outperform expert users in speed and isolation success in silico, and we demonstrate proof-of-concept isolation of a cancer cell from a spiked blood sample on-chip. MaGIC-OT provides a flexible framework for intelligent optical manipulation, aligning microfluidic device design with autonomous control strategies and offering a pathway toward high-purity, label-free single-cell workflows.
- 12 February 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (8) , 2451-2462
Open AccessMaGIC-OT: an AI-guided optical tweezers platform for autonomous single-cell isolation in microfluidic devices
Automating the isolation of rare cells such as circulating tumour cells (CTCs) within crowded microfluidic environments remains a bottleneck in liquid biopsy workflows. Optical tweezers offer contact-free, selective manipulation but traditionally rely on expert operators. We present MaGIC-OT (machine-guided isolation of cells using optical tweezers), a platform that integrates classical path planning and deep reinforcement learning (DRL) to automate single-cell manipulation inside a microfluidic chip. We built a high-fidelity simulation to train and benchmark control policies and show that cooperative, human-in-the-loop training improves DRL performance. Trained agents outperform expert users in speed and isolation success in silico, and we demonstrate proof-of-concept isolation of a cancer cell from a spiked blood sample on-chip. MaGIC-OT provides a flexible framework for intelligent optical manipulation, aligning microfluidic device design with autonomous control strategies and offering a pathway toward high-purity, label-free single-cell workflows.
- 11 December 2024
- Published by Georg Thieme Verlag KG in Frauenheilkunde up2date
- Vol. 18 (06) , 497-516
Die Rolle der Liquid Biopsy beim primären und metastasierten Mammakarzinom
Zirkulierende Tumor-DNA, CTCs und ctDNA, wird bereits erfolgreich im klinischen Alltag zur Prognoseprädiktion beim primären und metastasierten Mammakarzinom eingesetzt. In Zukunft wird der Einsatz der Liquid Biopsy möglicherweise noch deutlich zunehmen, da es derzeit viele vielversprechende Studien gibt. Im Rahmen dieses Artikels soll ein umfassender Blick auf den klinischen Einsatz von CTCs und ctDNA gerichtet werden unter Berücksichtigung der aktuellen Studienlage. Article published online: 11 December 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 11 December 2024
- Published by Georg Thieme Verlag KG in Frauenheilkunde up2date
- Vol. 18 (06) , 497-516
Die Rolle der Liquid Biopsy beim primären und metastasierten Mammakarzinom
Zirkulierende Tumor-DNA, CTCs und ctDNA, wird bereits erfolgreich im klinischen Alltag zur Prognoseprädiktion beim primären und metastasierten Mammakarzinom eingesetzt. In Zukunft wird der Einsatz der Liquid Biopsy möglicherweise noch deutlich zunehmen, da es derzeit viele vielversprechende Studien gibt. Im Rahmen dieses Artikels soll ein umfassender Blick auf den klinischen Einsatz von CTCs und ctDNA gerichtet werden unter Berücksichtigung der aktuellen Studienlage. Article published online: 11 December 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Top Cited Papers
- 4 January 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (1) , 307-318
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial
The phenotypes of tumor cells change during disease progression, but invasive rebiopsies of metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative metastatic breast cancer (MBC) patients with HER2-positive circulating tumor cells (CTCs) benefit from a HER2-targeted therapy. The open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited from March 2012 until September 2019 with a follow-up duration of 19.5 months. It was a multicenter clinical trial with 94 participating German study centers. A total of 2137 patients with HER2-negative MBC were screened for HER2-positive CTCs with a final modified intention-to-treat population of 101 patients. Eligible patients were randomized to standard therapy with or without lapatinib. Primary study endpoints included CTC clearance (no CTCs at the end of treatment) and secondary endpoints were progression-free survival, overall survival (OS), and safety. In both treatment arms CTC clearance at first follow-up visit—although not being significantly different for both arms at any time point—was significantly associated with improved OS (42.4 vs 14.1 months; P = 0.002). Patients treated additionally with lapatinib had a significantly improved OS over patients receiving standard treatment (20.5 vs 9.1 months, P = 0.009). DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for stratification of MBC cancer patients to HER2-targeting therapies. The OS benefit could be related to lapatinib, but further studies are required to prove this clinical observation. ClinicalTrials.gov Registration Number: NCT01619111.
- 4 January 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (1) , 307-318
Top Cited PapersEfficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial
The phenotypes of tumor cells change during disease progression, but invasive rebiopsies of metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative metastatic breast cancer (MBC) patients with HER2-positive circulating tumor cells (CTCs) benefit from a HER2-targeted therapy. The open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited from March 2012 until September 2019 with a follow-up duration of 19.5 months. It was a multicenter clinical trial with 94 participating German study centers. A total of 2137 patients with HER2-negative MBC were screened for HER2-positive CTCs with a final modified intention-to-treat population of 101 patients. Eligible patients were randomized to standard therapy with or without lapatinib. Primary study endpoints included CTC clearance (no CTCs at the end of treatment) and secondary endpoints were progression-free survival, overall survival (OS), and safety. In both treatment arms CTC clearance at first follow-up visit—although not being significantly different for both arms at any time point—was significantly associated with improved OS (42.4 vs 14.1 months; P = 0.002). Patients treated additionally with lapatinib had a significantly improved OS over patients receiving standard treatment (20.5 vs 9.1 months, P = 0.009). DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for stratification of MBC cancer patients to HER2-targeting therapies. The OS benefit could be related to lapatinib, but further studies are required to prove this clinical observation. ClinicalTrials.gov Registration Number: NCT01619111.
- Open Access
Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients
Background: The analysis of liquid biopsies, e.g., circulating tumor cells (CTCs) is an appealing diagnostic concept for targeted therapy selection. In this proof-of-concept study, we aimed to perform multiparametric analyses of CTCs to select targeted therapies for metastatic breast cancer patients. Methods: First, CTCs of five metastatic breast cancer patients were analyzed by whole exome sequencing (WES). Based on the results, one patient was selected and monitored by longitudinal and multiparametric liquid biopsy analyses over more than three years, including WES, RNA profiling, and in vitro drug testing of CTCs. Results: Mutations addressable by targeted therapies were detected in all patients, including mutations that were not detected in biopsies of the primary tumor. For the index patient, the clonal evolution of the tumor cells was retraced and resistance mechanisms were identified. The AKT1 E17K mutation was uncovered as the driver of the metastatic process. Drug testing on the patient’s CTCs confirmed the efficacy of drugs targeting the AKT1 pathway. During a targeted therapy chosen based on the CTC characterization and including the mTOR inhibitor everolimus, CTC numbers dropped by 97.3% and the disease remained stable as determined by computer tomography/magnetic resonance imaging. Conclusion: These results illustrate the strength of a multiparametric CTC analysis to choose and validate targeted therapies to optimize cancer treatment in the future. Furthermore, from a scientific point of view, such studies promote the understanding of the biology of CTCs during different treatment regimens.
Open AccessMultiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients
Background: The analysis of liquid biopsies, e.g., circulating tumor cells (CTCs) is an appealing diagnostic concept for targeted therapy selection. In this proof-of-concept study, we aimed to perform multiparametric analyses of CTCs to select targeted therapies for metastatic breast cancer patients. Methods: First, CTCs of five metastatic breast cancer patients were analyzed by whole exome sequencing (WES). Based on the results, one patient was selected and monitored by longitudinal and multiparametric liquid biopsy analyses over more than three years, including WES, RNA profiling, and in vitro drug testing of CTCs. Results: Mutations addressable by targeted therapies were detected in all patients, including mutations that were not detected in biopsies of the primary tumor. For the index patient, the clonal evolution of the tumor cells was retraced and resistance mechanisms were identified. The AKT1 E17K mutation was uncovered as the driver of the metastatic process. Drug testing on the patient’s CTCs confirmed the efficacy of drugs targeting the AKT1 pathway. During a targeted therapy chosen based on the CTC characterization and including the mTOR inhibitor everolimus, CTC numbers dropped by 97.3% and the disease remained stable as determined by computer tomography/magnetic resonance imaging. Conclusion: These results illustrate the strength of a multiparametric CTC analysis to choose and validate targeted therapies to optimize cancer treatment in the future. Furthermore, from a scientific point of view, such studies promote the understanding of the biology of CTCs during different treatment regimens.
- Open Access
- 1 August 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (8) , 101132
ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing
- 1 August 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (8) , 101132
Open AccessViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing
- Open Access
- 13 July 2020
- Published by Springer Nature in Breast Cancer Research
- Vol. 22 (1) , 1-16
Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression
Background: PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breast carcinogenesis. Nevertheless, little is known about the mechanisms by which PGRMC1 drives tumor progression. The aim of our study was to investigate the involvement of PGRMC1 in cholesterol metabolism to detect new mechanisms by which PGRMC1 can increase lipid metabolism and alter cancer-related signaling pathways leading to breast cancer progression. Methods: The effect of PGRMC1 overexpression and silencing on cellular proliferation was examined in vitro and in a xenograft mouse model. Next, we investigated the interaction of PGRMC1 with enzymes involved in the cholesterol synthesis pathway such as CYP51, FDFT1, and SCD1. Further, the impact of PGRMC1 expression on lipid levels and expression of enzymes involved in lipid homeostasis was examined. Additionally, we assessed the role of PGRMC1 in key cancer-related signaling pathways including EGFR/HER2 and ERα signaling. Results: Overexpression of PGRMC1 resulted in significantly enhanced proliferation. PGRMC1 interacted with key enzymes of the cholesterol synthesis pathway, alters the expression of proteins, and results in increased lipid levels. PGRMC1 also influenced lipid raft formation leading to altered expression of growth receptors in membranes of breast cancer cells. Analysis of activation of proteins revealed facilitated ERα and EGFR activation and downstream signaling dependent on PGRMC1 overexpression in hormone receptor-positive breast cancer cells. Depletion of cholesterol and fatty acids induced by statins reversed this growth benefit. Conclusion: PGRMC1 may mediate proliferation and progression of breast cancer cells potentially by altering lipid metabolism and by activating key oncogenic signaling pathways, such as ERα expression and activation, as well as EGFR signaling. Our present study underlines the potential of PGRMC1 as a target for anti-cancer therapy.
- 13 July 2020
- Published by Springer Nature in Breast Cancer Research
- Vol. 22 (1) , 1-16
Open AccessProgesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression
Background: PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breast carcinogenesis. Nevertheless, little is known about the mechanisms by which PGRMC1 drives tumor progression. The aim of our study was to investigate the involvement of PGRMC1 in cholesterol metabolism to detect new mechanisms by which PGRMC1 can increase lipid metabolism and alter cancer-related signaling pathways leading to breast cancer progression. Methods: The effect of PGRMC1 overexpression and silencing on cellular proliferation was examined in vitro and in a xenograft mouse model. Next, we investigated the interaction of PGRMC1 with enzymes involved in the cholesterol synthesis pathway such as CYP51, FDFT1, and SCD1. Further, the impact of PGRMC1 expression on lipid levels and expression of enzymes involved in lipid homeostasis was examined. Additionally, we assessed the role of PGRMC1 in key cancer-related signaling pathways including EGFR/HER2 and ERα signaling. Results: Overexpression of PGRMC1 resulted in significantly enhanced proliferation. PGRMC1 interacted with key enzymes of the cholesterol synthesis pathway, alters the expression of proteins, and results in increased lipid levels. PGRMC1 also influenced lipid raft formation leading to altered expression of growth receptors in membranes of breast cancer cells. Analysis of activation of proteins revealed facilitated ERα and EGFR activation and downstream signaling dependent on PGRMC1 overexpression in hormone receptor-positive breast cancer cells. Depletion of cholesterol and fatty acids induced by statins reversed this growth benefit. Conclusion: PGRMC1 may mediate proliferation and progression of breast cancer cells potentially by altering lipid metabolism and by activating key oncogenic signaling pathways, such as ERα expression and activation, as well as EGFR signaling. Our present study underlines the potential of PGRMC1 as a target for anti-cancer therapy.